Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04023877 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04023877: Completed Phase 1 study, sponsored by Eisai.
NCT04023877 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04023877, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of the study is to achieve mass balance recovery of \[14C\]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
Primary Outcome
Blood, urine, feces and toilet tissue samples will be collected at specific time points and will be analyzed for the amount of radiolabeled \[14C\]E2027.
Interventions
- DRUG E2027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-07-18 |
| Est. Completion | 2019-10-11 |
| Phase | Phase 1 |
What the finished NCT04023877 record still lists
NCT04023877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which E2027 is the first listed.
NCT04023877 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04023877 about?
NCT04023877 is a clinical study titled "A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants". The primary objective of the study is to achieve mass balance recovery of \[14C\]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
What is the current status of trial NCT04023877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-07-18. Estimated completion is 2019-10-11.
What interventions are being tested in trial NCT04023877?
The interventions under investigation include: E2027 (DRUG).
Who is sponsoring clinical trial NCT04023877?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04023877's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI